New Therapy Shows Promise in Platelet Disorder Trial

Got story updates? Submit your updates here. ›

Results from a phase 2 clinical trial show that the investigational medication mezagitamab can effectively boost platelet counts in patients with immune thrombocytopenia (ITP), an autoimmune disease characterized by elevated platelet destruction and reduced platelet production that increases bleeding risk and compromises quality of life.

Why it matters

This new therapy is especially meaningful given that approximately 20% of patients with ITP do not benefit from current therapies. The findings demonstrate the potential of this novel approach to target the underlying mechanism of the disease and rapidly normalize platelet counts.

The details

In the phase 2 clinical trial sponsored by Takeda Development Center Americas, researchers tested mezagitamab's potential against ITP. The study enrolled adults in several countries with ITP that had persisted for at least three months. Participants were randomized to receive mezagitamab at different doses or placebo. Treatment with mezagitamab led to increased platelet counts, with a safety profile similar to placebo. Through week 16, a platelet response was observed in 91% of participants in the mezagitamab 600-mg group compared to 23% in the placebo groups.

• The phase 2 clinical trial was conducted in 2025.
• The findings are published in the New England Journal of Medicine in April 2026.

What they’re saying

What’s next

The researchers are now conducting a phase 3 clinical trial of the 600-mg dose of mezagitamab, with Mass General Brigham Cancer Institute serving as the leading site in North America.